Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, skin disorder	Recruiting	Phase 1	2026-06-08		NCT04890613

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Senhwa Biosciences, Inc.	1

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre hospitalier de l'Université de Montréal (CHUM)	Montreal	Canada	1
Dana Farber Cancer Institute	Boston	United States	300
H. Lee Moffitt Cancer Center and Research Institute Hospital	Tampa	United States	1
Memorial Sloan-Kettering Cancer Center	New York	United States	63
Ohio State University-James Cancer Hospital and Solove Research Institute	Columbus	United States	1
Princess Margaret Cancer Centre	Toronto	Canada	9
University of California, Los Angeles	Santa Monica	United States	3
UPMC Hillman Cancer Center	Pittsburgh	United States	330